Cardiff Oncology, Inc. -> Nicht angegeben

Cardiff Oncology, Inc. has announced the completion of an asset acquisition under Item 2.01. The biotech company, which focuses on AI-powered cancer treatments, filed an 8-K report with the SEC documenting the completion of asset acquisition. Further details about the target and transaction value are expected in the attached financial statements.

AI-generated: summaries written by AI from the linked sources. How we use AI